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Abstract  
(61 words) 
The appropriateness of screening for amblyopia is an emotive issue, both within the United 
Kingdom (UK) and worldwide.  Recommendations within the UK state that children should 
be screened for visual impairment; yet there is evidence to suggest that such programmes are 
not cost-effective.  We aim to identify possible reasons as to why clinicians find the prospect 
of removing screening programmes unacceptable. 
  
Current UK recommendations state children should be screened for visual impairment, 
including amblyopia. [1]  Amblyopia is a condition which occurs in childhood and if left 
untreated well remain detectable throughout adult life.  The reported prevalence of amblyopia 
ranges from 2-5%.  [2]  Despite evidence suggesting screening for amblyopia is not cost-
effective [2],  the prospect of removing screening programmes is unacceptable from a 
FOLQLFLDQ¶VVWDQGSRLQWWe consider possible reasons for this. 
 
Consider this hypothetical question: 
 
Imagine the UK is preparing for a disease outbreak which may cause 600 fatalities.   
You have to choose between two vaccination schedules: Program A which will save 
200 people; and Program B which has a probability of saving all 600 people.  Which 
will you choose? 
 
Most people choose Program A.  However, if the question is framed differently a different 
response is received. 
You now have to choose between two different vaccination schedules: Program C will 
allow 400 people to die; and Program D which will let no people die with probability 
1 in 3, and a probability of 2 in 3 that all 600 will die.  Which will you choose? 
 
Most people choose Program D. [3]  The situations are identical in quantitative terms, but in 
the second question the decision-maker is losing instead of saving lives.  Setting zero lives 
lost as the status quo from which losses are measured makes the loss of 400 people more 
loathsome than the probable loss of 600.  This is known as loss aversion. 
 
Now consider the same example but with vision screening.   
 
Imagine two programmes for vision screening where up to 600 children could develop 
amblyopia.  Programme A will prevent 200 of these children becoming amblyopic; 
and Programme B will prevent all 600 becoming amblyopic with a probability of 1 in 
3.   
 
Most people will choose Program A.  However, if the question is framed differently a 
different response is received. 
 
You now have to choose between two different screening options:  Programme C will 
fail to prevent 400 children becoming amblyopic; and Programme D will prevent all 
600 becoming amblyopic with a probability of 1 in 3, and all 600 will become 
amblyopic with a probability of 2 in 3.  Which will you choose? 
 
Most people choose Program D.  Again, the situations are identical in quantitative terms, but 
in this scenario we are considering the number of children developing amblyopia if we stop 
screening.  The fact screening programmes already exist makes the prospect of removing 
them unappealing.  If there were no screening programme in place, any reduction would seem 
positive.  Policy makers are not keen to make active decisions which appear to increase harm.    
 
6HFRQGO\DYDLODELOLW\KHXULVWLFPD\EHDSSOLHG&OLQLFLDQVFDQRIWHQGUDZWRPLQG³RQHWKDW
ZRXOGKDYHJRWDZD\´EXWLJQRUHWKHQXPHURXVSHRSOHWHVWHGZLWKRXWUHDVRQ7KHRQO\
people that benefit from screening are those with the condition. Whilst clinicians may provide 
evidence and recall experiences of patients they have seen and treated, these occurrences 
PXVWEHSXWLQWRFRQWH[W7KLQNRIDOOWKHSHRSOHWKDWKDYHQ¶WEHHQVHHQLQYHVWLJDWHGDQG
treated.  Removing screening allows those resources to be allocated to cost-effective 
treatments.  
 
The final element may relate to benevolence ± the belief that it is better to do too many, than 
to miss a few.  Here the availability of treatment requires that it is given, regardless of the 
capacity to benefit the individual. 
 
Decisions of healthcare allocation ultimately involve cost, and the value that is placed upon 
health.  Frequently clinical and economic opinions differ ± understanding the reasoning 
behind these beliefs may address why such polarity in opinion occurs.  
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